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Background
•

With over 200,000 deaths annually worldwide, epithelial ovarian cancer (EOC) has the highest
mortality of all gynecologic cancers

•

Germline and somatic tumor tissue testing (TTT) for mutations in BRCA1/2 and assessment of
homologous recombination deficiency (HRD) informs prognosis and treatment decisions

•

In addition to BRCA1/2 mutation, HRD can be measured as either genomic instability (GI) or
loss of heterozygosity (LOH) and each is associated with different FDA approvals

•

NCCN guidelines (V1.2022) recommend germline and somatic testing and assessment
of HRD for all women with invasive EOC

•

Despite this recommendation, testing rates remain low and an optimal strategy to achieve the
recommended testing has not been defined

Objective
Evaluate rate, patterns
and trends over time of
germline and somatic
testing for invasive EOC
patients across a large
community-based
healthcare system
operating in five states

Methods
oStudy population
•patients with a diagnosis of invasive EOC (ICD C56.x)
•at least one in-person visit to a Providence St. Joseph Health (PSJH) oncology department or a PSJH oncology care provider for
EOC
•between January 2015 and January 2020 (n= 2847)
oData collected
•Patient demographics
•Clinicopathologic characteristics including tumor stage, treatment, and genetic counseling information
•Germline and somatic TTT information including time from diagnosis to receipt of test result in the EMR
•Structured genomic data was sourced from laboratory information systems and manual abstraction of molecular sequencing
reports
oData analysis
•Descriptive statistics were tabulated; Germline and somatic TTT data were analyzed separately. The term Genomic Testing (GT)
refers to patients who had either germline or somatic TTT

Genomic Testing Journey
•Germline testing was initial
testing approach in majority of
patients
•Of those with initial germline
or somatic testing, approximately
25% went on to receive
complement test
•Median time from diagnosis or
first contact to test order was >2x
longer for somatic vs. germline
testing
•Genetic counseling increased
testing rates but many patients did
not complete GC referral

Genomic Testing Trends
•GT rates increased over time
(p<0.0001), largely influenced by an
increase in somatic testing

Interval between germline and somatic
testing decreased dramatically over the
study period
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Genomic Testing Rates by Laboratory Assay
•Seventeen different vendors
and multiple assays were utilized
•Panel size varies greatly for
both germline (2-90 genes) and
somatic TTT (5-500 biomarkers)
•Extent of HRD analysis also
varies with unique
gene combinations in each panel
and LOH included on only 3 assays
•There is no consensus
regarding type of test to order
within this community-based cohort
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Conclusions
• Genomic testing (GT) rates for EOC patients have increased over time but remain low with less than 50% of
patients receiving GT at the end of the study interval
• Substantial heterogeneity exists in testing approach including the assay type, timing, and sequencing of test
• Genetic counseling greatly increased testing rates but only 15% of patients received a genetic counseling
referral
• We anticipate that a systematic, reflex testing protocol that incorporates engagement of genetic counseling
services and is limited to at most a few test vendors will improve adherence to guideline directed testing

